Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Yukio Kobayashi, Iekuni Oh, MD PhD, Toshihiro Miyamoto, MD PhD, Won-Sik Lee, Hiroatsu Iida, MD PhD, Hironobu Minami, MD PhD, Yoshinobu Maeda, MD PhD, Jun Ho Jang, Sung-Soo Yoon, MD PhD, Su-Peng Yeh, MD, Qui Tran, Joan Morris, Janet L. Franklin, Ka-Wing Chong, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 5069.

https://doi.org/10.1182/blood-2019-124582

Published: 2019

Journal Articles

Disease Burden Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Anthony S. Stein, MD, Zachary F. Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, MD, Max S. Topp, Janet L. Franklin, Ze Cong, PhD MS, Xinke Zhang, Yan Li, Andre Schuh

Blood (2018) 132 (Supplement 1): 3967.

https://doi.org/10.1182/blood-2018-99-115160

Published: 2018

Journal Articles

Age Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label, Phase 3 Study (TOWER)

Max S. Topp, Zachary F. Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, MD, Anthony S. Stein, MD, Janet L. Franklin, Ze Cong, PhD MS, Xinke Zhang, Andre Schuh

Blood (2018) 132 (Supplement 1): 5165.

https://doi.org/10.1182/blood-2018-99-115123

Published: 2018

Journal Articles

Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Luke Coyle, Nicholas J. Morley, Alessandro Rambaldi, MD, Kylie D. Mason, MBBS, MD FRACP, FRCPA, PhD, Gregor Verhoef, MDPhD, Caroline Furness, Alicia Zhang, A. Scott Jung, Janet L. Franklin

Blood (2018) 132 (Supplement 1): 400.

https://doi.org/10.1182/blood-2018-99-112280

Published: 2018

Journal Articles

Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG

Blood (2011) 118 (17): 4561–4566.

https://doi.org/10.1182/blood-2011-04-348888

Published: 2011

Includes: Supplemental data

Journal Articles

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

Hagop M. Kantarjian, Francis J. Giles, Peter L. Greenberg, Ron L. Paquette, Eunice S. Wang, Janice L. Gabrilove, Guillermo Garcia-Manero, Kuolung Hu, Janet L. Franklin, Dietmar P. Berger

Blood (2010) 116 (17): 3163–3170.

https://doi.org/10.1182/blood-2010-03-274753

Published: 2010

Journal Articles

Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

Phoenix A. Ho, Rong Zeng, Todd A. Alonzo, Robert B. Gerbing, Kristen L. Miller, Jessica A. Pollard, Derek L. Stirewalt, Nyla A. Heerema, Susana C. Raimondi, Betsy Hirsch, Janet L. Franklin, Beverly Lange, Soheil Meshinchi

Blood (2010) 116 (5): 702–710.

https://doi.org/10.1182/blood-2010-02-268953

Published: 2010

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine.

Peter L Greenberg, MD, Guillermo Garcia-Manero, MD, Michael R Moore, MD, Lloyd E. Damon, MD, Gail J. Roboz, MD, Helen Wei, Hagop Kantarjian, MD, Janet L. Franklin, MD, MPH

Blood (2009) 114 (22): 1769.

https://doi.org/10.1182/blood.V114.22.1769.1769

Published: 2009

Journal Articles

Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.

Roger M Lyons, Richard A. Larson, MD, Michael A. Kosmo, MD, Sunil Gandhi, Delong Liu, MD, PhD, Marc Chernoff, Luke Dreisbach, MD, Carmen Matei, Kuolong Hu, PhD, Janet L. Franklin, MD, MPH, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 1770.

https://doi.org/10.1182/blood.V114.22.1770.1770

Published: 2009

Journal Articles

High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group.

Walter B. Walter, MD, PhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MS, Franklin O. Smith, MD, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Alan S. Gamis, MD, Janet L. Franklin, MD, MPH, Craig A. Hurwitz, MD, Michael R. Loken, PhD, Soheil Meshinchi, MD, PhD

Blood (2009) 114 (22): 1592.

https://doi.org/10.1182/blood.V114.22.1592.1592

Published: 2009

Journal Articles

An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS).

Pierre Fenaux, Hagop Kantarjian, MD, Roger Lyons, Richard A. Larson, MD, Mikkael A. Sekeres, MD, MS, Pamela S. Becker, MD, PhD, Petra Muus, MD, PhD, Kuolong Hu, PhD, Dietmar Berger, MD, PhD, Janet L. Franklin, MD, MPH

Blood (2009) 114 (22): 2765.

https://doi.org/10.1182/blood.V114.22.2765.2765

Published: 2009

Journal Articles

Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.

Jason N. Berman, MD, Robert B. Gerbing, PhD, Lillian Sung, MD, Kristen Miller, BS, Jessica A. Pollard, MD, Phoenix Ho, Derek Stirewalt, Jerald Radich, MD, Craig A. Hurwitz, MD, Nyla A. Heerema, PhD, Betsy Hirsch, MD, Susana C. Raimondi, PhD, Beverly Lange, MD, Alan S. Gamis, MD, Janet L. Franklin, MD, MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD, PhD

Blood (2009) 114 (22): 3115.

https://doi.org/10.1182/blood.V114.22.3115.3115

Published: 2009

Journal Articles

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

Phoenix A. Ho, Todd A. Alonzo, Robert B. Gerbing, Jessica Pollard, Derek L. Stirewalt, Craig Hurwitz, Nyla A. Heerema, Betsy Hirsch, Susana C. Raimondi, Beverly Lange, Janet L. Franklin, Jerald P. Radich, Soheil Meshinchi

Blood (2009) 113 (26): 6558–6566.

https://doi.org/10.1182/blood-2008-10-184747

Published: 2009

Includes: Supplemental data

Journal Articles

Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

Nita L. Seibel, Peter G. Steinherz, Harland N. Sather, James B. Nachman, Cynthia DeLaat, Lawrence J. Ettinger, David R. Freyer, Leonard A. Mattano, Jr, Caroline A. Hastings, Charles M. Rubin, Kathy Bertolone, Janet L. Franklin, Nyla A. Heerema, Torrey L. Mitchell, Allan F. Pyesmany, Mei K. La, Cheryl Edens, Paul S. Gaynon

Blood (2008) 111 (5): 2548–2555.

https://doi.org/10.1182/blood-2007-02-070342

Published: 2008

Journal Articles

Minimal Residual Disease Detection by Four-Color Multidimensional Flow Cytometry Identifies Pediatric AML Patients at High Risk of Relapse.

Soheil Meshinchi, MD, PhD, Todd Alonzo, PhD, Robert B. Gerbing, MA, Jessica A. Pollard, MD, Alan S. Gamis, MD, MPH, Craig A. Hurwitz, MD, Janet L. Franklin, MD, Laura Pardo, MD, Michael Loken, PhD

Blood (2007) 110 (11): 1429.

https://doi.org/10.1182/blood.V110.11.1429.1429

Published: 2007

Journal Articles

A Phase I Study of Oral 6-Thioguanine, Followed by Continuous Infusion Cytarabine, Followed by Intramuscular PEG-Asparaginase (“TGAP”) in Children with Relapsed or Refractory Acute Leukemia or Non-Hodgkin’s Lymphoma.

Cecilia H. Fu, MD, Janet L. Franklin, MD, Paul Gaynon, MD, Colleen McCarthy, RN, Edward Panosyan, MD, Stuart E. Siegel, MD, Vassilios I. Avramis, MD

Blood (2006) 108 (11): 4536.

https://doi.org/10.1182/blood.V108.11.4536.4536

Published: 2006

NARROW

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Disease Burden Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Age Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label, Phase 3 Study (TOWER)

Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine.

Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.

High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group.

An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS).

Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

Minimal Residual Disease Detection by Four-Color Multidimensional Flow Cytometry Identifies Pediatric AML Patients at High Risk of Relapse.

A Phase I Study of Oral 6-Thioguanine, Followed by Continuous Infusion Cytarabine, Followed by Intramuscular PEG-Asparaginase (“TGAP”) in Children with Relapsed or Refractory Acute Leukemia or Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only